Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-102 combines our iTOL-100 technology with an inexhaustible supply of insulin producing allogeneic stem cell-derived pancreatic islets and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, allogenic pancreatic islet cells co-implanted with SA-FasL microgel exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression.
Development Pipeline
We Were 1 of 3 Companies Selected to Participate in the
Disruptive Healthcare Technology Showcase at the US Capital
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Bolsters Global Intellectual Property with Issuance of European Patent for Proprietary Regenerative SA-FasL Microgel Technology, iTOL-100
Company leveraging iTOL-100 to advance a pipeline of programs that have the potential to cure diseases, such as Type 1 Diabetes, without the need for life-long immunosuppressionMIAMI, FL / September 18, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), an...
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for the Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology
iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseasesManufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for...
iTolerance, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Live moderated video webcast with members of the iTolerance Leadership Team on Tuesday, July 11th 11:00 AM ETMIAMI, FL / July 6, 2023 / iTolerance, Inc. ("iTolerance" or the "Company"), a biotechnology company focused on the development of innovative regenerative...